Discover
AMLX
Amylyx Pharmaceuticals, Inc.
23.64
1 x 23.61
2 x 23.68
bid
ask
+
0.97
4.29%
01:32 PM
timesize
| Ytd | 95.71% | |
| 1y | 202.32% |
22.19
day range
23.73
7.63
52 week range
24.60
| Open | 23.15 | Prev Close | 22.67 | Low | 22.19 | High | 23.73 | Mkt Cap | 2.63B |
| Vol | 254.16K | Avg Vol | 1.66M | EPS | -1.50 | P/E | -15.77 | Forward P/E | -16.58 |
| Beta | -0.21 | Short Ratio | 6.93 | Inst. Own | 105.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 17.43 | 200-d Avg | 15.05 | 1yr Est | 28.33 |
| Income Statement | |||
| Operating Expenses | 45.69M | ||
| Research and Development Expense | 23.77M | ||
| Selling, General and Administrative Expense | 21.93M | ||
| Operating Income | -45.69M | ||
| Net Income | -43.42M | ||
| Net Income Common Stock | -43.42M | ||
| Net Income Common Stock (USD) | -43.42M | ||
| Consolidated Income | -43.42M | ||
| Earnings per Basic Share | -0.39 | ||
| Earnings per Basic Share (USD) | -0.39 | ||
| Earnings per Diluted Share | -0.39 | ||
| Earning Before Interest & Taxes (EBIT) | -43.42M | ||
| Earning Before Interest & Taxes (USD) | -43.42M | ||
| Weighted Average Shares | 111.20M | ||
| Weighted Average Shares Diluted | 111.20M | ||
| Balance Sheet | |||
| Cash and Equivalents | 50.31M | ||
| Cash and Equivalents (USD) | 50.31M | ||
| Investments | 201.43M | ||
| Investments Current | 201.43M | ||
| Current Assets | 256.34M | ||
| Property, Plant & Equipment Net | 4.74M | ||
| Total Assets | 264.56M | ||
| Debt Current | 1.01M | ||
| Total Debt | 5.26M | ||
| Current Liabilities | 21.15M | ||
| Debt Non-Current | 4.25M | ||
| Total Liabilities | 25.40M | ||
| Accumulated Retained Earnings (Deficit) | -836.13M | ||
| Accumulated Other Comprehensive Income | 19.00K | ||
| Shareholders Equity | 239.17M | ||
| Shareholders Equity (USD) | 239.17M | ||
| Assets Non-Current | 8.23M | ||
| Total Debt (USD) | 5.26M | ||
| Liabilities Non-Current | 4.25M | ||
| Trade and Non-Trade Payables | 5.53M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 43.00K | ||
| Net Cash Flow from Financing | 1.48M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -179.81M | ||
| Capital Expenditure | -30.00K | ||
| Issuance (Purchase) of Equity Shares | 1.97M | ||
| Net Cash Flow from Investing | -149.80M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -149.77M | ||
| Net Cash Flow from Operations | -31.42M | ||
| Effect of Exchange Rate Changes on Cash | -68.00K | ||
| Share Based Compensation | 8.32M | ||